John Bynon, MD
Transplant Surgery · Houston, TXNPI 1386684918
Payments from drug & device makers
What this record shows
7 manufacturers reported payments, led by Intuitive Surgical at 53.4% of the total. Reporting peaked in 2021 at $729 and has fallen 60.9% since, to $285 in 2024. That places this record below the midpoint for transplant surgery clinicians in TX, where the typical reported total is $2,154.
Across 17 payments — averaging $88.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$801
- Novartis$260
- Paragonix Technologies, Inc.$260
- Sanofi$101
- TELA Bio, Inc.$44
- Melinta Therapeutics, LLC$21
- plus $13 from 1 others
Across 4 payments — averaging $4079.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$16K
What the payments were for
- Travel & lodging$63042%
- Food & beverage$86958%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $801 |
| Novartis | 3 | $260 |
| Paragonix Technologies, Inc. | 1 | $260 |
| Sanofi | 1 | $101 |
| TELA Bio, Inc. | 3 | $44 |
| Melinta Therapeutics, LLC | 1 | $21 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$598
- SherpaPak$260
- LIVERguard$260
- LUNGguard$260
- BaroGuard$260
- PancreasPak$260
- THYMOGLOBULIN$101
How this compares
$1,499 in reported general payments places this provider in the 45th percentile of 70 transplant surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 27 | $67,848 |
| Tacrolimus | 410 | $66,004 |
| OzempicSemaglutide | 22 | $38,251 |
| CreonLipase/Protease/Amylase | 22 | $29,908 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $28,849 |
| VemlidyTenofovir Alafenamide | 12 | $19,789 |
| VeltassaPatiromer Calcium Sorbitex | 15 | $14,269 |
| TrulicityDulaglutide | 13 | $13,986 |
| VireadTenofovir Disoproxil Fumarate | 11 | $13,797 |
| Mycophenolate Mofetil | 185 | $13,123 |
| MounjaroTirzepatide | 12 | $12,621 |
| Ursodiol | 116 | $12,273 |
| Entecavir | 36 | $10,995 |
| EntrestoSacubitril/Valsartan | 13 | $8,780 |
| Tresiba Flextouch U-100Insulin Degludec | 16 | $7,317 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon | $13 | $29,90822 claims |
| NovartisEntresto | $260 | $8,78013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 70 transplant surgery providers in Texas.
Other transplant surgery in Houston
- Rafik GhobrialHouston$144K
- Constance MobleyHouston$56K
- David HallHouston$43K
- Ahmed GaberHouston$35K
- Nhu Thao GalvanHouston$22K
- Abbas RanaHouston$11K
- Chun-Sing HuangHouston$10K
- Charles VanburenHouston$9K
- John GossHouston$3K
- Rupak KulkarniHouston$253
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.